BridgeBio Pharma (BBIO) Payables (2019 - 2025)
BridgeBio Pharma (BBIO) has disclosed Payables for 7 consecutive years, with $36.2 million as the latest value for Q4 2025.
- Quarterly Payables rose 276.67% to $36.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.2 million through Dec 2025, up 276.67% year-over-year, with the annual reading at $36.2 million for FY2025, 276.67% up from the prior year.
- Payables hit $36.2 million in Q4 2025 for BridgeBio Pharma, up from $18.7 million in the prior quarter.
- In the past five years, Payables ranged from a high of $36.2 million in Q4 2025 to a low of $3.9 million in Q2 2023.
- Historically, Payables has averaged $13.7 million across 5 years, with a median of $11.1 million in 2022.
- Biggest five-year swings in Payables: crashed 60.62% in 2022 and later soared 482.17% in 2025.
- Year by year, Payables stood at $11.9 million in 2021, then dropped by 2.74% to $11.6 million in 2022, then decreased by 7.81% to $10.7 million in 2023, then dropped by 9.73% to $9.6 million in 2024, then surged by 276.67% to $36.2 million in 2025.
- Business Quant data shows Payables for BBIO at $36.2 million in Q4 2025, $18.7 million in Q3 2025, and $26.1 million in Q2 2025.